# US Liver Biopsy Market > US Liver Biopsy Market Research Report By Type (Percutaneous, Transjugular, Laparoscopic) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.74% - **2024:** $ 225.4 Million - **2025:** $ 236.08 Million - **2035:** $ 375 Million - **Key Players:** Abbott (US), Fujifilm (JP), Medtronic (US), Boston Scientific (US), Boehringer Ingelheim (DE), Siemens Healthineers (DE), Hologic (US), C.R. Bard (US), GE Healthcare (US) **Report ID:** MRFR/MED/17866-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-liver-biopsy-market-19413 --- ## Market Summary ## **US Liver Biopsy Market Overview** As per MRFR analysis, the US Liver Biopsy Market Size was estimated at 205.8 (USD Million) in 2023. The US Liver Biopsy Market Industry is expected to grow from 225.4(USD Million) in 2024 to 612.75 (USD Million) by 2035. The US Liver Biopsy Market CAGR (growth rate) is expected to be around 9.518% during the forecast period (2025 - 2035). ### **Key US Liver Biopsy Market Trends Highlighted** The US Liver Biopsy Market is shaped by several key market drivers, including the rising incidence of liver diseases, such as hepatitis c drugsand non-alcoholic fatty liver disease (NAFLD). As awareness of these conditions grows, public health initiatives in the US have emphasized the importance of early diagnosis and intervention, which increases the demand for liver biopsy procedures. Additionally, advancements in minimally invasive biopsy techniques are enhancing patient safety and comfort, thus driving more healthcare providers to adopt these procedures. Opportunities to be explored in the US market include the integration of artificial intelligence (AI) in diagnostic imaging, which could improve the accuracy and efficiency of liver biopsies.There is also a growing interest in non-invasive alternatives to traditional biopsies, which can offer safer and more convenient ways to diagnose liver conditions.  This shift in focus opens avenues for research and development in innovative diagnostic tools that cater to the needs of both clinicians and patients. Trends in recent times indicate an increasing emphasis on personalized medicine in the US liver biopsy landscape. Healthcare providers are adopting tailored treatment plans based on individual patient profiles, leading to a more targeted approach in managing liver diseases. Furthermore, regulatory bodies in the US are working to streamline the approval processes for new biopsy techniques and devices, which could facilitate quicker access to advanced technologies for clinicians.Overall, the US Liver Biopsy Market is poised for growth, driven by emerging technologies, changing patient demographics, and evolving healthcare standards. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Liver Biopsy Market Drivers** ### **Increasing Prevalence of Liver Diseases** The rise in liver diseases such as Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatitis is a significant driver for the US Liver Biopsy Market Industry. The American Liver Foundation states that between 25 to 30 percent of the U.S. population has NAFLD, which can lead to more serious liver conditions, including cirrhosis and liver cancer. This growing patient pool requires diagnostic tools like liver biopsy to monitor and assess liver health. With the National Institute of Diabetes and Digestive and Kidney Diseases estimating that approximately 4.5 million adults in the U.S.have chronic liver disease or cirrhosis, the demand for liver biopsy procedures will likely expand in the foreseeable future, further propelling the US Liver Biopsy Market. ### **Technological Advancements in Biopsy Procedures** Advancements in biopsy technologies, including imaging techniques such as ultrasound and MRI-guided biopsies, are enhancing the accuracy and safety of liver biopsies. These innovations have improved patient outcomes and reduced procedural risks. Research from the Radiological Society of North America has shown that image-guided biopsy procedures can diminish complication rates to as low as 1%. As the technology continues to evolve, healthcare providers are more inclined to adopt these methods, contributing to the growth of the US Liver Biopsy Market Industry. ### **Increased Awareness and Screening for Liver Health** There is a growing awareness of liver health among the general public, which is driving more individuals to seek screening and diagnostic procedures. The U.S. Centers for Disease Control and Prevention has initiated public health campaigns aimed at liver disease prevention and early detection, which stresses the importance of routine screenings for at-risk populations. This heightened awareness leads to a greater number of patients being referred for liver biopsies, thus increasing the demand within the US Liver Biopsy Market. ### **Rising Demand for Accurate Diagnostic Tools** An increasing focus on accurate diagnosis for liver diseases is spurring the demand for liver biopsy procedures. Clinicians and healthcare providers are recognizing the limitations of non-invasive tests, leading to a higher reliance on liver biopsies for definitive diagnosis. The American Gastroenterological Association has reported that liver biopsies remain the gold standard for assessing liver fibrosis. As more healthcare professionals advocate for precise diagnostic methods, the US Liver Biopsy Market Industry is expected to experience significant growth. ## **US Liver Biopsy Market Segment Insights** ### **Liver Biopsy Market Type Insights** The US Liver Biopsy Market segmentation by Type highlights the diverse approaches utilized for obtaining liver tissue samples, which include Percutaneous, Transjugular, and Laparoscopic techniques. Percutaneous biopsy, involving needle insertion through the skin to reach the liver, is one of the most common methods due to its minimally invasive nature and efficiency in diagnosing conditions such as hepatitis and cirrhosis. This technique has gained significant traction in recent years, particularly given the growing prevalence of liver diseases in the US, which has, in part, driven increased demand for more accurate and reliable diagnostic procedures. Transjugular biopsy, on the other hand, is often employed in cases where patients have coagulopathy or ascites, allowing for safer access to liver tissue without risking complications that could arise with percutaneous methods. Given the diverse patient populations in the US and the complexity of liver conditions, the versatility of the Transjugular technique plays a crucial role in the clinical decision-making process, ensuring that the best approach is utilized for each individual patient. Meanwhile, Laparoscopic biopsy, often regarded as a gold standard for certain cases requiring direct visualization of liver lesions, combines diagnosis with potential therapeutic interventions.  Its adoption reflects advancements in surgical techniques and technology, as well as a growing emphasis on providing comprehensive care in a single procedure. Overall, the Type segmentation of the US Liver Biopsy Market showcases the necessity for varied methods to cater to the diverse needs of patients and healthcare providers alike. With the increasing incidence of liver diseases and a rising focus on precision medicine in the US, these biopsy techniques are poised to play a vital role in enhancing diagnostic accuracy and improving patient outcomes. As the market evolves, each method’s unique advantages will contribute significantly to the overall growth of the US Liver Biopsy Market, underscoring the importance of continued innovation and development within the industry. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Liver Biopsy Market Key Players and Competitive Insights** The US Liver Biopsy Market showcases a landscape characterized by significant technological advancements and evolving clinical practices, leading to enhanced diagnostic precision and patient outcomes. This market is driven by an increasing prevalence of liver diseases, heightened awareness among healthcare professionals regarding the importance of early diagnosis, and the development of innovative biopsy techniques and devices. Competitive insights reveal a dynamic environment where well-established companies along with emerging players vie to capture market share through strategic initiatives such as product innovation, collaborations, and acquisitions. An emphasis on research and development is evident as companies strive to meet the growing demand for minimally invasive procedures aimed at liver health evaluation. This competitive intensity catalyzes improvement in methodologies and fosters a landscape conducive to better patient care and outcomes. Hologic has carved a substantial niche within the US Liver Biopsy Market by leveraging its strengths in innovative medical devices aimed at improving diagnostic processes. With a robust portfolio of proprietary technologies focused on imaging and biopsy solutions, Hologic emphasizes precision and patient safety, which are crucial in liver biopsy procedures. The company is known for its commitment to advancing women’s health and is increasingly applying its expertise to liver health diagnostics. Hologic’s market presence is underscored by a strong distribution network and strategic partnerships that enhance its ability to deliver quality products to healthcare providers. By continually investing in research and development, Hologic aims to further solidify its competitive edge and address the specific needs of the healthcare market in the US while focusing on patient-centered care. Merck also plays a prominent role in the US Liver Biopsy Market, shaping the competitive landscape through a range of key products and services designed for liver disease diagnosis and treatment. The company's strengths lie in its comprehensive research capabilities and robust product pipeline that includes a variety of diagnostic agents and biopsy solutions. Merck’s commitment to advancing liver health can be seen in its strategic collaborations and partnerships that facilitate innovative breakthroughs in the biopsy process. Moreover, the company actively engages in mergers and acquisitions to enhance its portfolio and market reach, ensuring its position at the forefront of the industry. With a firm presence in the US, Merck focuses on providing healthcare professionals with effective tools and technologies that contribute to improved patient outcomes in liver health management. As the company continues to innovate, it reinforces its stature as a key player in addressing the healthcare challenges associated with liver diseases. ### **Key Companies in the US Liver Biopsy Market Include** ### **US Liver Biopsy Market Industry Developments** The US Liver Biopsy Market has seen notable developments in recent months, particularly with advancements in minimally invasive techniques and imaging technologies. Companies such as Hologic and GE Healthcare are focusing on innovative biopsy methods that reduce patient discomfort while increasing diagnostic accuracy. Recently, Gilead Sciences reported a significant increase in their market valuation due to the growing emphasis on liver health and the rise in chronic liver diseases among the population. In terms of mergers and acquisitions, AbbVie completed the acquisition of Allergan in May 2020, with implications for expanding their liver disease portfolio, although it primarily targeted broader therapeutic areas.  Similarly, Merck is noted for exploring partnerships to enhance their liver biopsy solutions. The competitive landscape is intensifying, with BristolMyers Squibb and Siemens Healthineers also investing significantly in Research and Development related to liver disease diagnostics. Over the past few years, the emphasis on accurate diagnosis of liver conditions, largely attributed to the rising obesity epidemic, has catalyzed the growth of companies within this sector, thereby impacting the overall market dynamics positively. These developments are critical, considering the increasing urgency for innovative and reliable liver assessment tools in the US healthcare framework. ## **US Liver Biopsy Market Segmentation Insights** ### **Liver Biopsy Market Type Outlook** ## Market Drivers ### Rising Healthcare Expenditure The increase in healthcare expenditure in the US is another critical driver for the liver biopsy market. With healthcare spending projected to reach approximately $6 trillion by 2027, there is a growing investment in diagnostic services, including liver biopsies. This financial commitment from both public and private sectors is likely to enhance access to advanced diagnostic technologies and improve the overall quality of care. Additionally, as more healthcare providers adopt cutting-edge technologies, the liver biopsy market may benefit from increased utilization rates. The correlation between healthcare expenditure and the demand for diagnostic procedures suggests a positive outlook for the liver biopsy market in the coming years. ### Advancements in Biopsy Techniques Innovations in biopsy techniques are transforming the landscape of the liver biopsy market. The introduction of minimally invasive procedures, such as ultrasound-guided liver biopsies, has improved patient outcomes and reduced complications. These advancements not only enhance the accuracy of diagnoses but also increase patient comfort, which may lead to a higher acceptance rate of liver biopsies among patients. Moreover, the market is witnessing the development of new technologies, such as liquid biopsies, which could potentially offer less invasive alternatives to traditional methods. As these techniques gain traction, the liver biopsy market is likely to expand, driven by the demand for safer and more effective diagnostic options. ### Increasing Awareness of Liver Health The growing awareness regarding liver health among the population appears to be a significant driver for the liver biopsy market. Educational campaigns and initiatives by healthcare organizations are emphasizing the importance of early detection of liver diseases. This heightened awareness is likely to lead to an increase in the number of individuals seeking diagnostic procedures, including liver biopsies. As a result, the liver biopsy market may experience a surge in demand, particularly among high-risk populations. Furthermore, the prevalence of liver-related conditions, such as non-alcoholic fatty liver disease (NAFLD), is estimated to affect approximately 25% of the US population, which could further stimulate the market as more patients require accurate diagnosis and monitoring through liver biopsy procedures. ### Aging Population and Associated Health Issues The aging population in the US is contributing to the growth of the liver biopsy market. As individuals age, they are more susceptible to various liver diseases, including cirrhosis and liver cancer. This demographic shift is expected to increase the demand for diagnostic procedures, including liver biopsies, as healthcare providers seek to identify and manage liver-related conditions effectively. According to projections, the population aged 65 and older is expected to reach 80 million by 2040, which could significantly impact the liver biopsy market. The need for accurate diagnosis and timely intervention in this age group may drive the market forward, as healthcare systems adapt to the rising prevalence of liver diseases. ### Integration of Artificial Intelligence in Diagnostics The integration of artificial intelligence (AI) in diagnostic processes is emerging as a transformative force in the liver biopsy market. AI technologies are being utilized to enhance the accuracy of liver disease diagnosis and improve the interpretation of biopsy results. By analyzing vast amounts of data, AI can assist healthcare professionals in making more informed decisions regarding patient care. This technological advancement may lead to increased efficiency in the diagnostic process, potentially resulting in a higher volume of liver biopsies performed. As AI continues to evolve and gain acceptance in clinical settings, the liver biopsy market could see substantial growth driven by the demand for more precise and reliable diagnostic tools. ## Future Outlook The [Liver Biopsy Market](https://www.marketresearchfuture.com/reports/liver-biopsy-market-5534) is projected to grow at a 4.74% CAGR from 2025 to 2035, driven by advancements in diagnostic technologies and increasing prevalence of liver diseases. **New opportunities:** - Development of minimally invasive biopsy devices for outpatient settings. - Integration of AI-driven analytics for enhanced diagnostic accuracy. - Expansion of telehealth services for remote biopsy consultations. By 2035, the liver biopsy market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By Type: Percutaneous biopsy (Largest) vs. Transjugular biopsy (Fastest-Growing) In the US liver biopsy market, percutaneous biopsy holds the largest share, demonstrating its significance as the preferred method for clinicians. This segment showcases a wide acceptance due to its minimal invasiveness and efficiency, thus catering to a larger patient population. In contrast, while the transjugular biopsy segment occupies a smaller share, it has gained traction among healthcare professionals for complex cases, especially in patients with coagulopathy or ascites. Growth trends within these segments indicate a positive outlook for transjugular biopsy, which is deemed the fastest-growing segment. Factors contributing to this growth include increasing awareness of liver diseases and advancements in imaging technology that enhance the biopsy's efficacy and safety. Moreover, percutaneous biopsy is expected to remain steady, benefiting from ongoing improvements in technique and increased usage in outpatient settings. Biopsy Method: Percutaneous biopsy (Dominant) vs. Transjugular biopsy (Emerging) Percutaneous biopsy stands as the dominant method in the US liver biopsy market, favored for its straightforward approach, lower risk, and ability to yield accurate results with minimal patient discomfort. Its established positioning leads to robust clinical acceptance among practitioners, ensuring it remains the go-to method for liver tissue sampling. Meanwhile, the transjugular biopsy is emerging as an important option, particularly in patients with challenging anatomical considerations where percutaneous methods might not be suitable. This technique allows for direct access to the liver via the jugular vein, catering to a specific patient demographic with unique needs, thus presenting a complementary choice in the landscape of liver biopsy methodologies. ### By Indication: Nonalcoholic fatty liver disease (Largest) vs. Chronic hepatitis B or C (Fastest-Growing) The US liver biopsy market shows a diverse distribution among various indications, with nonalcoholic fatty liver disease holding the largest market share. This segment is driven by increasing obesity rates and rising awareness of liver diseases. Following closely, chronic hepatitis B or C is gaining momentum as awareness and testing initiatives expand, marking it as one of the fastest-growing segments in recent years. The growth trends in this market are primarily influenced by rising incidences of liver-related disorders. Factors such as lifestyle changes, increased alcohol consumption, and viral infections are pushing demand for liver biopsies across all segments. Innovative diagnostic techniques and greater access to healthcare are contributing to growth, especially in chronic hepatitis B or C, which is benefiting from enhanced treatment options and early detection strategies. Nonalcoholic fatty liver disease (Dominant) vs. Chronic hepatitis B or C (Emerging) Nonalcoholic fatty liver disease represents a dominant force in the US liver biopsy market, attributed to changing dietary patterns and higher rates of obesity, which have led to an increase in diagnoses. This segment's characteristics include a broader demographic appeal, affecting individuals regardless of alcohol intake. Conversely, chronic hepatitis B or C is an emerging segment, fueled by concerted public health efforts to combat viral infections. This segment is experiencing rapid growth due to improved screening and treatment options, catering especially to high-risk populations. Both segments illustrate varied yet significant market dynamics, where nonalcoholic fatty liver disease remains the leading indication, while chronic hepatitis B or C is on a notable upward trajectory. ### By End User: Hospitals & Clinics (Largest) vs. Tertiary Care Centers (Fastest-Growing) In the market segmentation based on end users, Hospitals & Clinics hold the largest share due to their extensive infrastructure and high patient footfall requiring liver biopsy procedures. Tertiary Care Centers follow, offering specialized and advanced services for liver diseases, leading to significant demand for biopsies. Urology Centers and other facilities also contribute, but their share is relatively smaller compared to the dominant players. Growth trends in the US liver biopsy market are shaped by increasing liver disease prevalence, advancements in biopsy techniques, and a rising emphasis on early diagnosis. The need for precision medicine and minimally invasive procedures drives demand within Hospitals & Clinics, while Tertiary Care Centers cater to complex cases, establishing themselves as the fastest-growing segment within the market. Hospitals & Clinics (Dominant) vs. Tertiary Care Centers (Emerging) Hospitals & Clinics are characterized by their broad accessibility and capability to accommodate a large volume of patients, making them the dominant force in the US liver biopsy market. They have the necessary resources and skilled personnel to conduct liver biopsies, thus playing a crucial role in patient management. On the other hand, Tertiary Care Centers represent an emerging segment that specializes in complex liver conditions, providing advanced diagnostic and therapeutic options. Their growth is fueled by increasing referrals from primary care physicians and the demand for specialized liver care, positioning them as indispensable in the evolving landscape of liver disease management. ## Competitive Benchmarking The liver biopsy market is characterized by a dynamic competitive landscape, driven by advancements in diagnostic technologies and an increasing prevalence of liver diseases. Key players such as Abbott (US), Medtronic (US), and Siemens Healthineers (DE) are strategically positioned to leverage innovation and enhance their operational focus. Abbott (US) emphasizes the development of minimally invasive biopsy techniques, which aligns with the growing demand for patient-centric solutions. Meanwhile, Medtronic (US) is focusing on expanding its product portfolio through strategic acquisitions, thereby enhancing its market presence. Siemens Healthineers (DE) is investing in digital transformation initiatives, aiming to integrate AI and machine learning into its diagnostic processes, which collectively shapes a competitive environment that prioritizes technological advancement and patient outcomes.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive innovation and set industry standards. This competitive structure fosters an environment where collaboration and strategic partnerships are essential for growth and sustainability. In October Abbott (US) announced the launch of a new line of biopsy devices designed to enhance precision and reduce recovery times for patients. This strategic move is likely to strengthen Abbott's position in the market by addressing the growing demand for less invasive procedures, thereby appealing to both healthcare providers and patients. The introduction of these devices may also enhance Abbott's competitive edge by differentiating its offerings in a crowded marketplace. In September Medtronic (US) completed the acquisition of a leading diagnostics firm specializing in liver disease detection technologies. This acquisition is strategically important as it allows Medtronic to expand its capabilities in the liver biopsy segment, potentially increasing its market share and enhancing its product offerings. The integration of advanced diagnostic technologies could lead to improved patient outcomes and solidify Medtronic's reputation as a leader in innovative healthcare solutions. In August Siemens Healthineers (DE) unveiled a new AI-driven platform aimed at streamlining the liver biopsy process. This platform is designed to assist clinicians in making more accurate diagnoses and treatment decisions. The strategic importance of this development lies in its potential to revolutionize the diagnostic landscape, making it more efficient and effective. By harnessing AI, Siemens Healthineers is likely to enhance its competitive positioning and appeal to a tech-savvy healthcare market. As of November current trends in the liver biopsy market indicate a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident. Companies that prioritize innovation and patient-centric solutions are likely to differentiate themselves in this evolving market. ## Recent News & Developments The US Liver Biopsy Market has seen notable developments in recent months, particularly with advancements in minimally invasive techniques and imaging technologies. Companies such as Hologic and GE Healthcare are focusing on innovative biopsy methods that reduce patient discomfort while increasing diagnostic accuracy. Recently, Gilead Sciences reported a significant increase in their market valuation due to the growing emphasis on liver health and the rise in chronic liver diseases among the population. In terms of mergers and acquisitions, AbbVie completed the acquisition of Allergan in May 2020, with implications for expanding their liver disease portfolio, although it primarily targeted broader therapeutic areas.  Similarly, Merck is noted for exploring partnerships to enhance their liver biopsy solutions. The competitive landscape is intensifying, with BristolMyers Squibb and Siemens Healthineers also investing significantly in Research and Development related to liver disease diagnostics. Over the past few years, the emphasis on accurate diagnosis of liver conditions, largely attributed to the rising obesity epidemic, has catalyzed the growth of companies within this sector, thereby impacting the overall market dynamics positively. These developments are critical, considering the increasing urgency for innovative and reliable liver assessment tools in the US healthcare framework. ## Report Scope | MARKET SIZE 2024 | 225.4(USD Million) | | --- | --- | | MARKET SIZE 2025 | 236.08(USD Million) | | MARKET SIZE 2035 | 375.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.74% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott (US), Fujifilm (JP), Medtronic (US), Boston Scientific (US), Boehringer Ingelheim (DE), Siemens Healthineers (DE), Hologic (US), C.R. Bard (US), GE Healthcare (US) | | Segments Covered | Type, Indication, End User | | Key Market Opportunities | Advancements in non-invasive techniques are reshaping the liver biopsy market landscape. | | Key Market Dynamics | Technological advancements and regulatory changes are reshaping the competitive landscape of the liver biopsy market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US liver biopsy market in 2024?** A: The market valuation of the US liver biopsy market was $225.4 Million in 2024. **Q: What is the projected market valuation for the US liver biopsy market by 2035?** A: The projected market valuation for the US liver biopsy market is $375.0 Million by 2035. **Q: What is the expected CAGR for the US liver biopsy market during the forecast period 2025 - 2035?** A: The expected CAGR for the US liver biopsy market during the forecast period 2025 - 2035 is 4.74%. **Q: Which type of biopsy had the highest valuation in 2024?** A: In 2024, the percutaneous biopsy had the highest valuation at $170.0 Million. **Q: What are the key indications driving the US liver biopsy market?** A: Key indications driving the US liver biopsy market include chronic hepatitis B or C, with a valuation of $120.0 Million in 2024. **Q: Which end user segment contributed the most to the market in 2024?** A: The hospitals & clinics segment contributed the most to the market in 2024, with a valuation of $150.0 Million. **Q: Who are the leading players in the US liver biopsy market?** A: Leading players in the US liver biopsy market include Abbott, Medtronic, and Boston Scientific. **Q: What was the valuation of the transjugular biopsy segment in 2024?** A: The transjugular biopsy segment had a valuation of $125.0 Million in 2024. **Q: How does the valuation of autoimmune hepatitis compare to other indications in 2024?** A: In 2024, the valuation for autoimmune hepatitis was $50.0 Million, which is lower than chronic hepatitis B or C but higher than alcoholic liver disease. **Q: What is the projected growth trend for the US liver biopsy market?** A: The US liver biopsy market is expected to grow steadily, reaching $375.0 Million by 2035, indicating a robust growth trend. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-liver-biopsy-market-19413*